3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
28
HER2-positive Breast Cancer
4
Neoplasms
3
Multiple Myeloma
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Lymphoma, Non-Hodgkin
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Brain Neoplasms
2
Anatomic Stage II Breast Cancer AJCC v8
2
Anatomic Stage I Breast Cancer AJCC v8
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Solid Tumors
1
Salivary Gland Neoplasms
1
Resectable HER2-positive Breast Cancer
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Meningeal Neoplasms
1
Meningeal Carcinomatosis
1
Melanoma
1
Malignant Solid Neoplasm
1
Lymphoma
1
Interventions
Paclitaxel
22
Bevacizumab
20
Carboplatin
19
liposomal doxorubicin
14
Specimen Handling
14
Magnetic Resonance Spectroscopy
13
olaparib
12
Topotecan
9
Gemcitabine
9
Biopsy
8
pembrolizumab
7
Taxes
6
Immunoglobulin G
6
Disulfides
6
niraparib
4
mirvetuximab soravtansine
4
cediranib
4
Doxorubicin
4
oregovomab
3
Nivolumab
3
Cyclophosphamide
3
sarilumab
2
rucaparib
2
cemiplimab
2
berzosertib
2
adavosertib
2
Oxaliplatin
2
Docetaxel
2
Cisplatin
2
Biosimilar Pharmaceuticals
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Fallopian Tube Neoplasms
×
pertuzumab
×
90 days
×
Clear all
No trials found.